# Sirtris Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sirtris-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.sirtrispharma.com
- Total disclosed funding: $67M
- Latest round: Series C (Mar 14, 2006)
- Investors on record: 17

## About

Sirtris Pharmaceuticals is focused on developing and commercializing innovative health products, primarily in nutritional supplements and over-the-counter medications, striving to improve health and wellness.Founded in 2004, Sirtris Pharmaceuticals is based in Cambridge, US, specializing in health product development. The company underwent a significant shift when it was acquired by GlaxoSmithKline in April 2008 for USD 720 mn. It has executed a total of 7 deals, with its most recent deal occurring on May 23, 2007. The company's founder, who is not specified in the data, has an undisclosed history with other ventures.Sirtris Pharma specializes in the development and commercialization of health and wellness products, with a focus on nutritional supplements and over-the-counter medications. Their flagship product, Solgar Magnesium Citrate, is recognized for its bioavailability. The company also offers sugar-free cookies tailored for diabetics and remedies for ailments such as nasal congestion and gastrointestinal discomfort, serving consumers and healthcare professionals across North America, Europe, and selected regions in Asia.In the most recent year, 2007, Sirtris Pharma reported a revenue of USD 0 and an EBITDA of USD -34,564,000. The company's revenue model is primarily based on direct sales of its health products through retail partnerships and direct-to-consumer channels, including bulk orders of flagship products and promotional discounts.Following its IPO in May 2007, where Sirtris Pharmaceuticals raised USD 60 mn by selling 6 million shares at USD 10.00 per share, the company was subsequently acquired by GlaxoSmithKline in April 2008 for USD 720 mn. Future initiatives are focused on expanding their product line and entering new markets, although specific products and timelines have not been detailed in the current data.

## Funding rounds

- Series C, Mar 14, 2006, $22M — Cardinal Partners, Wellcome Trust, TVM Capital Life Science, Polaris Partners, Three Arch Partners, Novartis Venture Fund, Skyline Ventures, Covera Ventures, Alexandria Venture Investments, Red Abbey, Cycad Group, Cargill Ventures, Bessemer Venture Partners, Hercules Capital, Sanofi Ventures, QVT funds
- Series B, Mar 7, 2005, $27M — Cardinal Partners, Wellcome Trust, Polaris Partners, Three Arch Partners, Novartis Venture Fund, Skyline Ventures, Covera Ventures, Cargill Ventures, TVM Capital
- Series A, Nov 17, 2004, $13M — Cardinal Partners, Wellcome Trust, TVM Capital Life Science, Polaris Partners, Skyline Ventures
- Series A, Aug 16, 2004, $5M — Cardinal Partners, Polaris Partners, Skyline Ventures, TVM Capital

## Investors

- Cardinal Partners (https://capitalatlas.ai/funds/cardinal-partners) — Series A, Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C
- TVM Capital (https://capitalatlas.ai/funds/tvm-capital) — Series A, Series B
- Wellcome Trust — Series A, Series B, Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series C
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C
- Covera Ventures (https://capitalatlas.ai/funds/covera-ventures) — Series B, Series C
- Cargill Ventures (https://capitalatlas.ai/funds/cargill-ventures) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series C
- Cycad Group (https://capitalatlas.ai/funds/cycad-group) — Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series C
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series C
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series C
- QVT funds — Series C